Navigation Links
Allergens, Inhalants/Foods, Pacific Northwest Profile

ProductsAllergens, Inhalants/Foods, Pacific Northwest Profile
Company ARUP Laboratories
Item Allergens, Inhalants/Foods, Pacific Northwest Profile
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Allergens, Animal, Dog/Cat Epithelium Profile
2. Allergens, Animal Epithelium/Dander/Feather Mix Profile
3. Allergens, Food, Cereal Profile
4. Allergens, Dust/Mite Profile
5. Allergens, Food, Comprehensive Profile 1
6. Allergens, Food, Common Adult Food
7. Allergens, Food, IgG Panel 18
8. Allergens, Food, Nut Mix Profile
9. Allergens, Food, Profile 13
10. Allergens, Food, Profile 19
11. Allergens, Food, Profile 4
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches.
Yag Laser System SYL is compact and light-weight. It is CE Mark approved according to MDD.
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish.
Farnsworth panel D15 test evaluation has a choice of 4 easy ways to arrange caps with automatic creation 'horse-shoe' diagrams, automatic color deficiency analysis, manual color deficiency analysis,
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...and that rocks the cradle rules the world! Rightly... child from the moment of birth. //Enabling the ch...not be mere wishful-thinking, and in this age of i...clearly understood, as a foundation for all round ...
... blood test developed by Dr. Edward A. Hirschowitz... early stages in people who are at high risk for d...ing cause of cancer death in United States and aro... diagnosed at a later stage. The incidence of lun...
...rches have found that different genes may be invol...e also noted that other genes may also be involved...pmental disorder in a new study published in the o... Genetics. The study also provides new evidence f...
...orld's first and only cervical cancer vaccine, Gar...s that causes most cervical cancers, may go on sal...he vaccine developed by US pharmaceutical company ...nt effective against the two main strains of the H...
Other Medicine News:Health News:Breast Milk: The Mother of All Milk for Infants 2Health News:Breast Milk: The Mother of All Milk for Infants 3Health News:New Blood Test For Early Detection Of Lung Cancer 2Health News:New Findings on Autism Research 2
(Date:9/4/2008)... SAN MATEO, Calif., Sept. 4 /PRNewswire-FirstCal... announced that the pivotal clinical study of,Poli... partner, Chemische,Fabrik KREUSSLER & Co. GmbH (K...oint and has been submitted to FDA as part of a Ne... clinical study, named the EASI (Efficacy and safe...
(Date:9/4/2008)...Pivotal Study Seeks to Enroll 750 Women at More Th... 4 /- QuatRx Pharmaceuticals, a,priva...elopment and,commercialization of compounds to tre...rs, today announced that it has initiated a second...tablets), the company,s,estrogen-free oral therapy...
(Date:9/4/2008)... Data Announcements Remain on Schedule with Two A...Clinical Data Release in November 2008, BRIDGEWAT...euticals,Inc., a specialty pharmaceutical company...tabolic disease, today announced the appointment o...of directors., Peter Garrambone,s career includes...
(Date:9/3/2008)... - Long term follow up results from chronically ... exceed positive data obtained earlier in 2008, ...ficant and long-term antiviral effect of th...he way and strongly support move into a second gen...vant IC31(R) acting through TLR ...
Breaking Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4AVMA Opens Online Resource to General Public 16418 1AVMA Opens Online Resource to General Public 16418 2Diabetes in Middle Age Raises Alzheimers Risk 16413 1Diabetes in Middle Age Raises Alzheimers Risk 16413 2Diabetes in Middle Age Raises Alzheimers Risk 16413 3Professionals Use Drugs to Sharpen Their Minds Survey Finds 16408 1Professionals Use Drugs to Sharpen Their Minds Survey Finds 16408 2Professionals Use Drugs to Sharpen Their Minds Survey Finds 16408 3 24250 000 Grant Awarded to National Hospice and Palliative Care Organization from Technology Grant Program 16403 1 24250 000 Grant Awarded to National Hospice and Palliative Care Organization from Technology Grant Program 16403 2 24250 000 Grant Awarded to National Hospice and Palliative Care Organization from Technology Grant Program 16403 3 24250 000 Grant Awarded to National Hospice and Palliative Care Organization from Technology Grant Program 16403 4
...* Significant blood sugar reductions seen across r...ic groups, the elderly,and those at high risk of ...when added to a sulfonylurea,reinforcing efficacy...nes , * Data confirm good tolerability in humans w...lar to placebo in monotherapy,trials , * European ...
...ata Also Support Drug,s Efficacy at Improving Glyc...Complications, CHICAGO, Ill., June 23, 2007 /PRNew...s commercialization partner S2 Therapeutics,Inc.,...ical trial,supporting the overall and cardiovascul...tion of bromocriptine mesylate) in subjects,with t...
Other Medicine Technology:New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 2New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 3New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 5New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 6Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5